Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Alkaloids Stories

2010-06-07 08:00:00

Results Presented at ASCO 2010 Annual Meeting Confirm Acceptable Safety Profile and Evidence of Biological Activity Including Declines in Circulating Tumor Cells and Reductions in Tumor Markers BOTHELL, WA, and VANCOUVER, June 7 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various...

2010-06-07 00:30:00

CHICAGO, June 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response. A pathological complete response, observed in 32% of patients, is recorded only when the esophagus...

2010-05-24 00:34:00

SEATTLE, May 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that phase II study results from Brown University will be presented by Kimberly Perez, M.D., Hematology/Oncology Fellow with the Warren Alpert School of Medicine of Brown University, at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Sunday, June 6, 2010. The abstract, #4085, title is "Neoadjuvant Paclitaxel Poliglumex (PPX), Cisplatin and...

2010-05-10 13:30:00

SOUTH SAN FRANCISCO, Calif., May 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010. The Company reported a net loss of $11.9 million ($0.29 diluted loss per share on a loss applicable to common shares of $12.5 million) for the quarter ended March 31, 2010. As of March 31, 2010, cash and investment securities totaled...

2010-05-06 07:00:00

PHILADELPHIA, May 6 /PRNewswire/ -- URL Pharma, Inc., today announced that the U.S. Food and Drug Administration (FDA) has issued new label information affecting all approved protease inhibitors for treatment of HIV when co-administered with Colcrys® (colchicine, USP). These dosing guidelines are intended to avoid potentially fatal drug-drug interactions. These new dosing recommendations were issued as a result of several clinical studies designed and conducted by URL...

2010-04-22 07:00:00

PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC...

2010-04-20 08:00:00

CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010. XMT-1001 is a conjugate of the anti-cancer molecule...

2010-03-31 11:54:00

PHILADELPHIA, March 31 /PRNewswire/ -- A newly-published clinical study demonstrates that Colcrys® (colchicine, USP), a low-dose oral colchicine, is just as effective as high-dose colchicine in reducing pain associated with early acute gout flare, but with a safety profile statistically indistinguishable from placebo. The study, "High vs. Low-dosing of Oral Colchicine for Early Acute Gout Flare: Twenty-Four Hour Outcome Results of the First Randomized,...

2010-03-15 15:20:00

PHILADELPHIA, March 15 /PRNewswire/ -- URL Pharma, Inc. today announced the launch of an expanded Colcrys® (colchicine, USP) Patient Assistance Program (PAP) that significantly increases the number of patients eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes of up to 6 times the federal poverty level are eligible for the new Colcrys PAP. This expanded program is available to patients immediately. Colcrys is indicated...

2010-03-09 06:30:00

CALGARY, March 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2009. "In 2009, we executed on our business plan focused on preparing the Company for late stage clinical testing and ultimately commercial launch by making substantial clinical progress, strengthening our intellectual property position and balance sheet, and scaling up...